About Us Contact Us

Contact Us

Send 

Search

 

The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma

Paulina Chinchilla-López, Xingshun Qi, Eric M. Yoshida, Nahum Méndez-Sánchez

Abstract

The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon-based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.

Key words. This article does not has key words., Liver, Cancer, Drugs, Hepatitis

Article Metrics

The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for the Study of the Liver and the Canadian Association for the Study of the Liver

ALEH Hepatología CASL ACEF Médica Sur
Index Copernicus PubMed

© 2016 Annals of Hepatology. All rights reserved Privacy Policy